Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations

AIDS

Volumn 13, Issue 3, 1999, Pages 359-365

  Schapiro, Jonathan M ^a   Winters, Mark A ^a   Lawrence, Jody ^a   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Cross resistance; HIV; Indinavir; Protease inhibitors; Resistance mutations; Saquinavir

Indexed keywords

CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; VIRUS LOAD; VIRUS MUTATION;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MUTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SAQUINAVIR; VIRAL LOAD; ZIDOVUDINE;

EID: 0032969551     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902250-00008     Document Type: Article

References (33)

1. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
2. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
3. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
4. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV- infected patients. Ann Intern Med 1996, 124:1039-1050.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
6. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998, 351:543-549.
7. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anfiretroviral therapy. N Engl J Med 1997, 337:734-739.
8. Hammer SM, Squires KE, Hughes MD, et al.: Controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
9. Wong JK, Gunthard HF, Havlir DV, et al.: Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997, 94:12574-12579.
10. Markowitz M, Conant M, Hurley A, et al.: A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998, 177:1533-1540.
11. Jacobsen H, Hanggi M, Ott M, et al.: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996, 173:1379-1387.
12. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
13. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV-1 protease confers resistance to ritonavir. Nat Med 1996, 2:760-766.
14. Shafer RW, Winters MA, Palmer S, Merigan TC: Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-911.
15. Gunthard HF, Wong JK, Ignacio CC, et al.: Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998, 72:2422-2428.
16. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF: Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996, 276:1955-1956.
17. 3 (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998, 177:617-624.
18. Fätkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
19. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
20. Schmit JC, Ruiz L, Clotet B, et al.: Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10:995-999.
21. Roberts NA, Craig JC, Sheldon J: Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998, 12:453-460.
22. Winters M, Tan LB, Katzenstein DA, Merigan TC: Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol 1993, 31:2960-2966.
23. Lin HJ, Myers LE, Yen-Leiberman B, et al.: Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994, 170:553-562.
24. Wood R, Dong H, Katzenstein DA, Merigan TC: Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells. J Acquir Immune Defic Syndr 1993, 6:237-240.
25. Cohen J: AIDS trials ethics questioned. Science 1997, 276:520-523.
26. Lange JMA: Current problems in the future of antirelroviral drug trials. Science 1997, 276:548-550.
27. Jacobsen H, Yasargil K, Winslow DL, et al.: Characterisation of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro31-8959. Virology 1995, 206:527-534.
28. Winters MA, Schapiro JM, Lawrence J, Merigan TC: Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998, 72:5303-5306.
29. Zolopa AR, Shafer RW, Warford A, Montoya JG, Katzenstein DA, Merigan TC: Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Second International Workshop on Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 1998 [abstract 54].
30. Herrigan PR, Montaner JS, Hogg RS, et al.: Baseline resistance profiles predicts response to ritonavir/saquinavir therapy in a community setting. Second International Workshop on Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, Month? 1998 [abstract 55].
31. Patick AK, Zhang M, Hertogs K, et al.: Correlations of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Second International Workshop on Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, Month? 1998 [abstract 57].
32. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
33. Hirsch MS, Conway B, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998, 279:1984-1991.